2023
Long-Term Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention Among Medicare Beneficiaries
Almarzooq Z, Tamez H, Wang Y, Curtis J, Kirtane A, Secemsky E, Valsdottir L, Yeh R. Long-Term Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention Among Medicare Beneficiaries. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100584. PMID: 39129810, PMCID: PMC11307545, DOI: 10.1016/j.jscai.2023.100584.Peer-Reviewed Original ResearchNon-CTO percutaneous coronary interventionCTO percutaneous coronary interventionPercutaneous coronary interventionLong-term major adverse cardiovascular eventsChronic total occlusion (CTO) percutaneous coronary interventionMajor adverse cardiovascular eventsAdverse cardiovascular eventsHospital eventsHigh riskCardiovascular eventsCoronary interventionMyocardial infarctionLower riskNational Cardiovascular Data Registry CathPCI RegistryST-elevation myocardial infarctionHospital event ratesElevation myocardial infarctionLong-term outcomesRepeat revascularizationStable anginaCathPCI RegistryResults PatientsTerm outcomesPCI proceduresMedicare beneficiaries
2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo group
2015
Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®
Ghanbari H, Nallamothu BK, Wang Y, Curtis JP. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®. Journal Of The American Heart Association 2015, 4: e001331. PMID: 25637345, PMCID: PMC4345865, DOI: 10.1161/jaha.114.001331.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAtrial FibrillationCoronary Artery DiseaseDefibrillators, ImplantableDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansIncidenceMaleMedicareMiddle AgedPatient DischargePlatelet Aggregation InhibitorsRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationCoronary artery diseaseMajor adverse cardiovascular eventsNational Cardiovascular Data RegistryAdverse cardiovascular eventsDevice-related complicationsAntithrombotic agentsDefibrillator implantationArtery diseaseAtrial fibrillationAntithrombotic therapyBleeding riskCardiovascular eventsThromboembolic eventsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryImplantable Cardioverter-Defibrillator RegistryHigh bleeding riskCombination of DAHospital dischargeICD implantationPrimary outcomeData registryPatientsFibrillation